ODAIA Intelligence

ODAIA Intelligence is a Canadian company developing a cloud platform for pharmaceutical companies. The service uses AI and analysis of various information, for example, demographic and socio-economic data on citizens, to predict the most effective sales channels for medicines being developed.

History

2022: Raising $13.8 million

On February 11, 2022 the ODAIA company reported about attraction of $13.8 million investment within a round of financing of series A. It was headed by fund with the Russian roots Flint Capital with the participation of Innospark Ventures, Alumni Ventures, Graphite Ventures and the current investors of BDC Capital's Women in Tech Fund, MaRS IAF, StandUp Ventures, Panache Ventures and others. Andrew Herschfeld, who is a partner at Flint Capital, will advise ODAIA and represent Flint on ODAIA's board of directors. Also on the board of directors of ODAIA will be Matt Faith, venture partner at Innospark Ventures.

The funds will be used by the company to expand the capabilities of the platform, as well as to expand sales, marketing and successful customer relations to support an expanded market presence.

Fund with Russian roots Flint Capital invested in the developer of the cloud platform for pharmaceutical companies ODAIA Intelligence

Some of the early functions of the study focused on analyzing individual journeys and working with artificial intelligence and machine learning to improve these journeys, says DAIA founder Filip Pulidis. - Over time, the platform evolved and began to include things like evaluating multiple separate but related information resources, such as prescription transactions, anonymized data on individual health and fitness applications, demographic and socioeconomic population information, anonymized laboratory data, and more. All of these research and engineering developments led to the creation of MAPTUAL, a SaaS platform that analyzes the aforementioned knowledge sets to obtain prognostic information, prioritization, and a dynamic section of physicians who work with customers who are excellent candidates for targeted therapeutics.

The company believes that the COVID-19 pandemic has improved the situation with buyers in the small pharmaceutical business and that digital transformation is now a priority. As for the long-term perspective, Pulidis said that the goal of the startup is to offer a single platform for multidimensional analysis of information and prediction of lifestyle information. He noted that the platform will include attributes and capabilities that will allow companies engaged in the sciences of existence to better understand the path of their doctors and people and respond to them in real time using data and artificial intelligence.^[1]

Notes